Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy.
about
Role of cancer-associated fibroblasts in invasion and metastasis of gastric cancerMicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysisDiagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocolMicroRNA-106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma?Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinomaImpact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava.Treatment-independent miRNA signature in blood of Wilms tumor patients.Patterns of microRNA expression in non-human primate cells correlate with neoplastic development in vitro.Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma.miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.Expression and clinical significance of the microRNA-200 family in gastric cancer.Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma.KRT6 interacting with notch1 contributes to progression of renal cell carcinoma, and aliskiren inhibits renal carcinoma cell lines proliferation in vitro.Novel classes of non-coding RNAs and cancerMicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone.Expression of miR-27a-3p is an independent predictive factor for recurrence in clear cell renal cell carcinoma.Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomasExpression and functional role of miR-29b in renal cell carcinoma.MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients.The regulation and function of microRNAs in kidney diseases.Differential microRNA expression in renal cell carcinoma.Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer.A genetic variant in the promoter region of miR-106b-25 cluster predict clinical outcome of HBV-related hepatocellular carcinoma in Chinese.Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs.The epigenetics of renal cell tumors: from biology to biomarkers.MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma.MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review).Downregulation of miR-193a-3p inhibits cell growth and migration in renal cell carcinoma by targeting PTEN.Effect of miR-106b on Invasiveness of Pituitary Adenoma via PTEN-PI3K/AKT.MicroRNA-495 suppresses human renal cell carcinoma malignancy by targeting SATB1.Biomarkers of Renal Tumors: the Current State and Clinical Perspectives.miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma.The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney.Prognostic value of meta-signature miRNAs in renal cell carcinoma: an integrated miRNA expression profiling analysisCombination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinomaMiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients.A Lasso regression model for the construction of microRNA-target regulatory networks.MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma.
P2860
Q26781520-E0928F94-9B1C-4A66-8545-D84DA2C8A030Q26785371-8688B271-C5C9-4676-9549-9C5F30975B02Q28071747-828E176B-4E34-4041-A424-F3F201A3A248Q28384675-C589CB8A-19A8-41AA-AA33-FC38C260D085Q30318519-BBA12699-F1AD-47F6-BDD3-60BC19235B63Q34152578-5FD5E48D-4D52-4B1F-A063-C9629B98BB78Q34287632-CC00507E-93DD-4A70-ABFD-C85398CE267EQ34370023-ECEC3196-97C6-4261-AB36-8A721EA41FE9Q34434075-65E03F9E-3188-4106-A759-0A636B174197Q34667439-BA438B62-255B-450A-8DF4-772965885ADEQ35551941-39EC60F2-4F03-4BEA-A60A-5D768B0F2239Q35742259-3E16DBE6-3070-4062-89DE-8225E72B6587Q35922727-747FB0DB-EAFF-47F1-9871-E79830E25A36Q36095196-E7DDA6F5-ED8D-411B-A62C-0EFD62961FD8Q36209417-3A6FF6E7-1AD9-44D9-A131-22731C8E1522Q36326306-FC4A3267-46CF-4D87-8630-AF98016E016BQ36356425-CAB88D28-2FE0-4CD4-B543-1603EBDF1BA6Q36382323-FDD60CE5-8183-4EC8-A157-56D0ED32310AQ36464365-36524B48-B9EB-4AD5-9184-225888F6A5F8Q36522330-2FF05754-569B-4766-9B41-AB5BE807DC6EQ36960910-13737566-0F02-4DDA-A0F9-4A4AD6738E86Q37211359-7FF84B88-2244-429B-9BD4-87D80EDCAC89Q37295196-DD8ABF58-97B2-47D6-903B-3BAD16F9E0F3Q37453234-C0D9B793-4A24-4E5F-AE1F-C60BD2D91447Q37514211-8B304690-D637-4D05-A0AD-B982EEB08059Q37828424-3CE15D2D-EA54-4A0C-B090-2DCBA1E57635Q38016153-7DAE9333-96E7-422F-97A7-E0CF7511A842Q38261708-61C01B07-9A36-40FC-8298-A9D3BB3D9D82Q38356005-0566326C-F1F5-4D47-ACBD-FEBD342481C6Q38699390-761769A8-4771-4322-A029-94E1F34FD207Q38712436-40A5D6B7-61B8-4D29-B8E8-BF8290464D34Q38929235-CF52A21F-9258-4AE3-9499-7BBC5758A39CQ39097822-3834142C-085E-425E-B2AE-FE98D0647834Q39255366-3022257B-DC9B-4363-AACF-72EC1DCF5647Q39257795-90FDA177-06A5-4148-B68F-966C44B2522CQ40652931-EB456FAA-C2F8-431D-98AA-1C68D0E5EFB7Q41883434-4BC8F555-112C-4BC3-8B5D-AEF1D945CF5EQ42317002-43452273-1B0C-4A32-9CD9-9CF4E55CB180Q42608545-B13E1A1F-1D1A-4968-B56B-C405C8D31968Q43440363-9B499347-9B49-40BB-954A-50DDCF915A4B
P2860
Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Expression of miRNA-106b in co ...... metastasis after nephrectomy.
@ast
Expression of miRNA-106b in co ...... metastasis after nephrectomy.
@en
Expression of miRNA-106b in co ...... metastasis after nephrectomy.
@nl
type
label
Expression of miRNA-106b in co ...... metastasis after nephrectomy.
@ast
Expression of miRNA-106b in co ...... metastasis after nephrectomy.
@en
Expression of miRNA-106b in co ...... metastasis after nephrectomy.
@nl
prefLabel
Expression of miRNA-106b in co ...... metastasis after nephrectomy.
@ast
Expression of miRNA-106b in co ...... metastasis after nephrectomy.
@en
Expression of miRNA-106b in co ...... metastasis after nephrectomy.
@nl
P2093
P2860
P356
P1476
Expression of miRNA-106b in co ...... metastasis after nephrectomy.
@en
P2093
Alexandr Poprach
Jana Jancovicova
Jaroslav Michalek
Marek Svoboda
Ondrej Slaby
Pavel Fabian
Radek Lakomy
Rostislav Vyzula
P2860
P2888
P356
10.1186/1756-9966-29-90
P577
2010-07-07T00:00:00Z
P5875
P6179
1015255225